JPIAMR 14th Call Partner Search Tool

General Information

• Type: Partner looking for project
• Organisation: University of Milano - Bicocca
• Country: Italy (IT)

Research area

• Scientific area(s) of the call:
  1. Improvement of drug/plant protection agent efficacy and/or specificity through chemical modifications (including hit to lead optimisation)
  2. Design and implementation of innovative tools, including novel chemistry and/or new materials for improved application, efficacy and delivery of antimicrobials
• One Health Setting:

  Human Health

• Type of studies/experimental approaches:

  in silico, in vitro, in vivo

• Keywords:

  AMR deep characterization; clinical isolates; AST; new patented compounds

• Brief description of your expertise / expertise you are looking for:

  We are a microbiology laboratory, interested in developing new compounds to combat the challenges of AMR through interdisciplinary research. Our lab is based in the Department of Medicine, University of Milano-Bicocca (second public University of Milan, Italy) and we work in collaboration with various leading drug discovery and synthesis teams on rationale drug design of new compounds as antibiotics, disinfectants and efflux pump inhibitors (EPIs). We have a long-standing experience in AMR characterization and AST. We maintain a collection of clinical isolates as part of the JRU MIRRI-IT, with defined both antibiotic susceptibility/resistance profiles to be used in screening tests to validate new compounds, new associations of antibiotics and potentiators and new strategies for rationale drug design.

• Brief description of your project / the project you would like to join:

  We have previously identified and patented resistance-breaking compounds as a new serie of oxazolidinones that overcome bacterial resistance to the antibiotic class, including in clinical strains where multidrug resistance already exists. Importantly, these compounds function with an improved mechanism of action, and are also capable of inhibiting bacterial strains in which all known mutations and consequent ribosomal and protein modifications are present. We are performing hit-to-lead studies and preclinical studies for bioavailability optimization. Another field of interest is the development of EPIs to be associated with new and confirmed antibiotics.

Rosario Musumeci

• Organisation: University of Milano - Bicocca
• Position: Assistant Professor in Clinical Microbiology
• E-mail: rosario.musumeci@unimib.it
• Phone: 0039 02 6448 8103
• Web: en.unimib.it/rosario-musumeci